Schering-Plough/Sandoz Leucomax (molgramostim or GM-CSF)
Executive Summary
U.K. launch of for chemotherapy-induced neutropenia in cancer patients, for acceleration of recovery following autologous bone marrow transplantation, and for the treatment of ganciclovir- induced neutropenia in AIDS patients with cytomegalovirus retinitis, announced by the companies. The regulatory submission was filed in 1990. Schering and Sandoz are jointly developing Leucomax for the U.S. market.